Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01069003 · ClinicalTrials.gov registry record · Phase 4
EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events
A Phase 4 study, sponsored by Medtronic Vascular.
- Completed
- Registry status
- Phase 4
- Development phase
- 2,272
- Enrollment target
NCT01069003 is a Phase 4 study that has completed, run by Medtronic Vascular. The registered enrollment target is 2,272 participants.
The verdict
NCT01069003, a Phase 4 study, has completed, sponsored by Medtronic Vascular.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 2,272 participants
- Enrollment target
Study Summary
EDUCATE is a prospective, multi-center study designed to collect real-world safety and clinical outcomes in subjects receiving one or more Endeavor Zotarolimus-Eluting Stents and either clopidogrel and aspirin or prasugrel and aspirin as part of a dual antiplatelet therapy (DAPT) drug regimen.
Interventions
- DRUG Placebo Arm
- DRUG Thienopyridine Therapy
- DEVICE Surveillance Arm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,272 participants |
| Start Date | 2010-04 |
| Est. Completion | 2014-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01069003
The ClinicalTrials.gov registry entry for NCT01069003 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 2,272 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Vascular, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo Arm is the first listed.
NCT01069003 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01069003 about?
NCT01069003 is a clinical study titled "EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events". EDUCATE is a prospective, multi-center study designed to collect real-world safety and clinical outcomes in subjects receiving one or more Endeavor Zotarolimus-Eluting Stents and either clopidogrel and aspirin or prasugrel and aspirin as part of a dual antiplatelet therapy (DAPT) drug regimen.
What is the current status of trial NCT01069003?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 2,272 participants. The study started on 2010-04. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01069003?
The interventions under investigation include: Placebo Arm (DRUG), Thienopyridine Therapy (DRUG), Surveillance Arm (DEVICE).
Who is sponsoring clinical trial NCT01069003?
This trial is sponsored by Medtronic Vascular, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.